Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (MCRPC).

According to the new European Physician & Payer Forum report entitled Will Emerging Agents for Prostate Cancer Achieve Acceptance from Payers and Prescribers in Europe?, surveyed oncologists in France, Germany, Italy, Spain and the United Kingdom say that efficacy is overwhelmingly the most important factor dictating the uptake of emerging therapies for MCRPC.

"Emerging agents need to improve efficacy over current standards of care in order to penetrate the market," said Decision Resources Analyst Andrew Merron, Ph.D. "The barrier is lower in the asymptomatic MCRPC setting where clinicians are dependent on hormonal therapies, while barriers are greater in the symptomatic MCRPC setting where Sanofi-Aventis's Taxotere (docetaxel), the gold-standard, is widely prescribed. As a result, most agents in clinical trials are being used in combination with Taxotere for symptomatic MCRPC."

In symptomatic MCRPC, the majority of patients will receive a Taxotere-containing regimen one year following the launch of emerging therapies. Celgene's Revlimid and Bristol-Myers Squibb's Sprycel and zibotentan will compete to partner with Taxotere. After considering reimbursement hurdles in their countries, overall, French and Italian oncologists assign the greatest patient share to Sprycel and zibotentan. However, the greatest patient share of any regimen will be attributed to Taxotere/prednisone alone with no emerging therapy additions.

In non-metastatic castrate-resistant prostate cancer (NMCRPC), Amgen's Prolia has considerable commercial potential assuming it can gain approval as an anti-neoplastic agent (and improve bone metastases-free survival). Significant commercial potential in the NMCRPC setting arises from the large drug-treatable pool and potentially long treatment durations.

The report also finds that abiraterone use in the asymptomatic setting is the only emerging therapy in NMCRPC or first-line MCRPC which is likely to secure a favorable NICE appraisal, according to the majority of surveyed oncologists in the United Kingdom. Interviewed payers indicate that the premium prices of emerging therapies, (notably Revlimid and Provenge) may limit uptake although generic docetaxel will help stimulate use of emerging therapies used in combination with docetaxel because of an overall reduced cost of the regimen.

The report is based on a survey of 251 oncologists from Germany (50), France (50), Italy (51), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... Inc. Magazine Unveils ... at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, ... Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The list ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Employers , an international competition, were announced today. The awards recognize the world’s ... suppliers who help to create and drive great places to work. , A ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) ... President, Chief Medical Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, ... for BHI’s cutting-edge analytics solutions. , “I am thrilled to welcome Dr. Spiro ...
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... their recently launched community enrichment program. Partnering once again with Boys & Girls ... competition to help find the area’s very own American Idol. With all proceeds ...
Breaking Medicine News(10 mins):